U.S., Nov. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07223307) titled 'REGULUS: MRI-guided Adaptive SABR for Liver Cancers' on Oct. 23.
Brief Summary: Single arm unblinded study of simulation-free MRI-guided SABR with adaptive replanning in one session for treatment of patients with liver cancers
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Liver Cancer
Intrahepatic Cholangiocarcinoma
Liver Metastases
HCC
Intervention:
RADIATION: MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
A single fraction of MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) will be delivered using the MRIdian system. Treatment includes adaptive planning based on dail...